Search In this Thesis
   Search In this Thesis  
العنوان
Fibroblast growth factor 23 in multiple myeloma patients with renal impairment /
المؤلف
Abdelallim, Nada Shawky Rizk.
هيئة الاعداد
باحث / ندى شوقي رزق عبد العليم
مشرف / أمل مصطفى محمد العفيفي
مشرف / نور الهدى حسين عبد الله
مناقش / ناهد معوض ابراهيم
تاريخ النشر
2021.
عدد الصفحات
152p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب الباطني
تاريخ الإجازة
1/1/2021
مكان الإجازة
جامعة عين شمس - كلية الطب - باطنة عامة
الفهرس
Only 14 pages are availabe for public view

from 152

from 152

Abstract

FGF23 is a new emerging factor in medical field it is
thought to be responsible for phosphate metabolism by
increasing its excretion in renal impairment patients and
decrease vitamin D level in them. It is thought that its
expression increases in multiple myeloma patients
increasing heparenase. Heparenase is an osteolytic factor
which increases morbidity in multiple myeloma patients.
So studies were done on FGF23 with a hope that we can
use it to predict stages of renal impairment, control vitamin
D decline in renal impairment or stop FGF23 axis in
multiple myeloma as this axis thought to increase morbidity
in multiple myeloma patient.
In our study we measured IFGF23 level in multiple
myeloma patients with and without renal impairment and
compared results with renal impairment patients without
multiple myeloma and healthy individuals.
 Serum iFGF23 was higher in patients with multiple
myeloma than the control subjects (P < 0.01).
 Serum iFGF23 level higher in multiple myeloma
patients with renal impairment than those without
renal imparment (p<0.05)
 Serum iFGF23 level higher in renal impairment
patients than in healthy individuals (p<0.01).
 There is significant direct correlation between iFGF23
and creatinine (p<0.01), (r=0.689).
(111
)
 Summary
 Serum iFGF23 is significantly inversely proportional
to eGFR (p<0.01), (r=0.678).
 We found that FGF23 is not correlated to Hb, Na, k,
LDH, ca, B2 micro, BM plasma cells, D bilirubin,
ALT, AST.
 Moreover it was found in our study that FGF23 has a
cut off point greater than or equal to 135pg/ml to
predict multiple myeloma patients with renal
impairment from multiple myeloma without renal
impairment with sensitivity 70% and specificity 75%.
 However we discovered that FGF23 has a cut off point
greater than or equal to 62.5pg/ml to predict multiple
myeloma patients from healthy individuals with
sensitivity 80%.